Quick answer
How is a CJC-1295 (No DAC) + ipamorelin blend reconstituted, and what do published animal studies say about its components? The V8 product page describes a 1:1 mass blend of the two peptides in one co-lyophilized vial, sold as 5 mg / 5 mg or 10 mg / 10 mg, ≥98% HPLC purity, stored at 2–8 °C with −20 °C for the long term. Reconstitution is dissolution plus arithmetic: each peptide's mass concentration equals its mass ÷ diluent volume, and because the masses are equal the two mass concentrations are equal, while the molar concentrations are not. Ipamorelin (about 712 Da from its formula) is a much smaller molecule than CJC-1295 No DAC (about 3,368 Da), so a 1:1 mass blend holds roughly 4.7 ipamorelin molecules for every CJC-1295 molecule. Published preclinical work on the components used rat pituitary cells, anaesthetised rats and swine, reported in nmol per kg. This article sets out the formulas and how to read those papers. For laboratory research use only.
Most reconstitution questions about this blend come down to two worries: how to calculate each peptide's concentration, and what concentration or amount the research literature used. Both can be answered without recommending anything. This guide gives the formulas, shows why equal mass does not mean equal molarity, summarizes what the primary papers on each component reported, and explains how a researcher compares a stock with those papers. It complements the background pieces CJC-1295 + ipamorelin research overview and blend explained, and the procedural reconstitution and storage article. All content concerns laboratory work; the product is for laboratory research use only and not for human consumption.
The two molecules
The blend product page pairs a growth hormone-releasing hormone analog with a ghrelin-receptor agonist. The single-compound pages list the formulas: CJC-1295 (No DAC) as C152H252N44O42 and ipamorelin as C38H49N9O5.
| Property | CJC-1295 (No DAC) | Ipamorelin |
|---|---|---|
| Class | Modified GRF (1-29), GHRH analog | Selective pentapeptide GHS-R1a agonist |
| Sequence | Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Ser-Arg | Aib-His-D-2-Nal-D-Phe-Lys-NH2 |
| Length | 29 residues | 5 residues |
| Molar mass from formula | About 3,368 Da | About 712 Da |
| Receptor | GHRH receptor | Ghrelin receptor (GHS-R1a) |
| Main handling concern | Deamidation and surface loss in solution | Small and robust; adsorption at low concentration |
Equal mass, unequal molarity
The arithmetic follows from three relationships, written as formulas because the numbers depend on the vial and the diluent volume.
- Mass concentration of a component = component mass ÷ diluent volume. In a 1:1 vial the two component masses are equal, so the two mass concentrations are equal and the total is twice either one.
- Molar concentration = mass concentration ÷ molar mass, so it must be computed separately for each peptide.
- Molar ratio = (mass of A ÷ molar mass of A) ÷ (mass of B ÷ molar mass of B). For equal masses this reduces to the inverse ratio of molar masses, about 3,368 ÷ 712 ≈ 4.7 ipamorelin per CJC-1295.
The product page makes the same point in words: equal mass does not mean equal molarity. This matters whenever an experiment is designed in molar terms, for example when comparing a receptor-binding result with a published EC50 in nmol per liter. A mass-based stock cannot be compared with a molar-based paper until it has been converted. The reconstitution calculator handles the volume step, its guide explains the inputs and volume calculations covers the reasoning. Net peptide content may be lower than the weighed fill because of counterions and bound water; where a certificate reports it, use it.
What the primary papers report
Parameters are listed as the abstracts state them. Reading them accurately is more useful than any summary.
| Paper | System | Compound | What was reported |
|---|---|---|---|
| Raun et al., 1998 | Primary rat pituitary cells | Ipamorelin | GH release with potency and efficacy similar to GHRP-6; EC50 of about 1.3 nmol per liter reported |
| Raun et al., 1998 | Pentobarbital-anaesthetised rats | Ipamorelin | GH release comparable to GHRP-6; ED50 about 80 nmol per kg reported |
| Raun et al., 1998 | Conscious swine | Ipamorelin | GH release with ED50 about 2.3 nmol per kg; no significant release of ACTH or cortisol at levels beyond 200-fold above the ED50 reported |
| Jetté et al., 2005 | Cultured rat pituitary cells and male Sprague Dawley rats | hGRF(1-29)-albumin bioconjugates, including CJC-1295 | Enhanced stability against DPP-IV; subcutaneous administration produced acute GH secretion; best compound showed about a 4-fold GH area under the curve versus hGRF(1-29) over 2 h; plasma presence beyond 72 h |
| Cunha and Mayo, 2002 | Cells expressing transfected GHRH and secretagogue receptors | Ghrelin and GH secretagogues with GHRH | Secretagogues potentiated GHRH-induced cAMP production |
Three points of interpretation follow. First, the CJC-1295 in the Jetté paper is the albumin-binding maleimide form, which is the variant that carries the DAC group; the No DAC product on the V8 page is the unconjugated modified GRF (1-29), whose action is short and pulse-like, as CJC-1295 DAC vs No DAC explains. That paper therefore supports the design logic for the family, not any property of the No DAC peptide itself. Second, ED50 and EC50 values are properties of a particular assay, species and anaesthetic state. Third, the Cunha and Mayo result is the in vitro basis for the idea that a GHRH analog and a ghrelin-receptor agonist act together: the two receptors converge on cAMP and calcium signaling in somatotrophs. Whether any result with the blend is additive or synergistic can only be established with single-compound arms.
Reconstitution and handling
- Equilibrate the sealed vial to room temperature before opening.
- Choose the vial size first. The same diluent volume gives different concentrations in the two sizes, as the formulas above show.
- Diluent. Bacteriostatic water for a vial that will be entered repeatedly; sterile water for single-use frozen aliquots. Match it in the vehicle control.
- Add slowly down the vial wall and swirl gently. A 29-residue peptide aggregates under agitation; do not shake or vortex.
- Aliquot into low-binding tubes, freeze those not needed at once and thaw each aliquot once. The page notes that short GHRH analogs lose integrity with repeated temperature cycling.
- Record lot, date, vial size, diluent, volume, mass and molar concentrations of both components and appearance.
Deamidation of asparagine and glutamine in GRF analogs in neutral aqueous solution was described by Friedman and colleagues (1991), and the broader mechanisms of peptide instability are reviewed by Manning and colleagues (2010). Surface adsorption is described by Goebel-Stengel and colleagues (2011). In practice the CJC-1295 half of the blend is the less robust of the two, so a stock should be judged by how it holds up, and the ipamorelin half will usually outlast it. General procedure is in how to reconstitute a lyophilized peptide, and shelf life in how long reconstituted peptides last.
Checking that the vial matches the label
The blend page says the certificate is reported where published; the COA library lists those that exist. A useful certificate for a two-peptide vial shows two resolved peaks of the expected relative area, the method and the identity result for each. CJC-1295 + ipamorelin purity testing and how to read a COA cover the fields. For a single number the calculation should be written beside the certificate: if the blend is labeled 1:1 by mass, the area ratio of the two peaks is not expected to be 1:1, because UV response per mass differs between a 5-residue and a 29-residue peptide.
A note on units and records
Concentrations in papers appear in three families of units: mass per volume, moles per volume and amount per kilogram of body weight. A stock prepared in mass per volume can be compared with a molar figure only after dividing by molar mass, and can be compared with a per-kilogram figure only if the delivered volume and the animal weight are known, which is outside bench work. Writing the conversion beside each stock, with the molar mass used and its source, makes the record readable months later. For this blend that means two lines per vial, one for each peptide, each with mass concentration, molar mass and molar concentration. A third line for the total mass concentration is useful for checking that the arithmetic closes: the two component mass concentrations should sum to the total. When the calculator is used, filing its output with the record removes transcription errors.
Design notes for a two-receptor experiment
- Include arms for CJC-1295 alone, ipamorelin alone, the blend and a vehicle.
- Use a cell system in which both receptors are present if combined signaling is the question, or separate single-receptor cells if the question is attribution.
- Express concentrations in molar terms, with the mass-to-molar conversion in the record.
- Compare with CJC-1295 vs ipamorelin and the broader ipamorelin research overview for context.
- Decide in advance whether a single blended vial or separate vials better fits the question.
Nothing in this article is a recommendation for use in people or animals. The product is supplied for laboratory research use only. Other materials are in the shop.
Frequently asked questions
What does the blend product page list?
A 1:1 mass co-lyophilized blend of CJC-1295 (No DAC) and ipamorelin in 5 mg / 5 mg and 10 mg / 10 mg vials, ≥98% HPLC purity, stored at 2–8 °C with −20 °C for the long term.
How is each peptide's concentration calculated?
Component mass divided by diluent volume. In a 1:1 vial the two mass concentrations are equal and the total is double either one.
Why is a 1:1 mass blend not 1:1 by molecules?
Ipamorelin is about 712 Da and CJC-1295 No DAC about 3,368 Da, so equal masses contain roughly 4.7 ipamorelin molecules per CJC-1295 molecule.
How is molar concentration calculated?
Mass concentration divided by molar mass, calculated separately for each peptide. The calculator does the volume step.
What did the ipamorelin paper study?
Primary rat pituitary cells, anaesthetised rats and conscious swine, reporting GH release with ED50 values in nmol per kg and a lack of ACTH or cortisol release at high multiples of the ED50 (Raun and colleagues, 1998).
Does the CJC-1295 albumin-conjugate paper apply to the No DAC peptide?
Only to the design logic. The Jetté paper studied an albumin-binding maleimide form; the No DAC peptide is the unconjugated modified GRF (1-29) with a short, pulse-like action.
What does the in vitro synergy paper show?
Cunha and Mayo reported that ghrelin and secretagogues potentiated GHRH-induced cAMP production in cells expressing both receptors.
How should the solution be mixed and stored?
Add diluent slowly down the vial wall, swirl without shaking, aliquot into low-binding tubes, freeze extra aliquots at once and thaw each once.
How are the sealed vials stored?
The product page states 2–8 °C, with −20 °C for the long term, protected from heat, moisture and light.
Is the blend for use in people or animals?
No. It is supplied for laboratory research use only and is not for human or animal consumption.
Related reading: CJC-1295 and Ipamorelin Animal Studies: Methods Guide.
References
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552
- Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286
- Cunha SR, Mayo KE. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-4582. doi:10.1210/en.2002-220670
- Friedman AR, Ichhpurani AK, Brown DM, Hillman RM, Krabill LF, Martin RA, Zurcher-Neely HA, Guido DM. Degradation of growth hormone releasing factor analogs in neutral aqueous solution is related to deamidation of asparagine residues. Int J Pept Protein Res. 1991;37(1):14-20. doi:10.1111/j.1399-3011.1991.tb00727.x
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. doi:10.1007/s11095-009-0045-6
- Goebel-Stengel M, Stengel A, Taché Y, Reeve JR Jr. The importance of using the optimal plasticware and glassware in studies involving peptides. Anal Biochem. 2011;414(1):38-46. doi:10.1016/j.ab.2011.02.009
